医疗设备制造商波士顿科学(BSX)10月23日盘中股价大跌5.04%,引发市场广泛关注。
分析人士表示,导致股价大跌的主要原因是波士顿科学暂停了旗下心脏设备Farapulse的一项临床试验。该试验旨在将Farapulse作为治疗持续性心房颤动的一线疗法,但公司称出现"一些意料之外的观察结果",因此决定暂停试验。
尽管波士顿科学上调了2024财年利润预期至每股2.45至2.47美元,高于之前预期,并且第三季度利润和收入也超出华尔街预期,但暂停重要产品的临床试验显然引发了市场对公司产品效果与安全性的质疑和担忧。分析人士认为,如果Farapulse无法如期上市销售,将对波士顿科学未来盈利造成负面影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.